{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:31Z","timestamp":1787019631852,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2407-10-677","type":"journal-article","created":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T05:35:41Z","timestamp":1295415341000},"source":"Crossref","is-referenced-by-count":47,"title":["Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase"],"prefix":"10.1186","volume":"10","author":[{"given":"Uffe H","family":"Olesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob G","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Garten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wieland","family":"Kiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ichiro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette K","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fristrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemette V","family":"Thougaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Bj\u00f6rkling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren J","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Sehested","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,12]]},"reference":[{"issue":"9","key":"2476_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrd2871","volume":"8","author":"PA Janne","year":"2009","unstructured":"Janne PA, Gray N, Settleman J: Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 2009, 8 (9): 709-723. 10.1038\/nrd2871.","journal-title":"Nat Rev Drug Discov"},{"issue":"5531","key":"2476_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293 (5531): 876-880. 10.1126\/science.1062538.","journal-title":"Science"},{"issue":"4","key":"2476_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00062752-200207000-00007","volume":"9","author":"ME Gorre","year":"2002","unstructured":"Gorre ME, Sawyers CL: Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol. 2002, 9 (4): 303-307. 10.1097\/00062752-200207000-00007.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2476_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","volume":"16","author":"T O'Hare","year":"2006","unstructured":"O'Hare T, Corbin AS, Druker BJ: Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev. 2006, 16 (1): 92-99. 10.1016\/j.gde.2005.11.002.","journal-title":"Curr Opin Genet Dev"},{"issue":"6","key":"2476_CR5","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1046\/j.1432-1327.2000.01187.x","volume":"267","author":"M Ziegler","year":"2000","unstructured":"Ziegler M: New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem. 2000, 267 (6): 1550-1564. 10.1046\/j.1432-1327.2000.01187.x.","journal-title":"Eur J Biochem"},{"issue":"7-8","key":"2476_CR6","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00018-004-4503-3","volume":"62","author":"J Diefenbach","year":"2005","unstructured":"Diefenbach J, Burkle A: Introduction to poly(ADP-ribose) metabolism. Cell Mol Life Sci. 2005, 62 (7-8): 721-730. 10.1007\/s00018-004-4503-3.","journal-title":"Cell Mol Life Sci"},{"issue":"37","key":"2476_CR7","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1038\/sj.onc.1210616","volume":"26","author":"LR Saunders","year":"2007","unstructured":"Saunders LR, Verdin E: Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007, 26 (37): 5489-5504. 10.1038\/sj.onc.1210616.","journal-title":"Oncogene"},{"issue":"6","key":"2476_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","volume":"13","author":"G Kroemer","year":"2008","unstructured":"Kroemer G, Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008, 13 (6): 472-482. 10.1016\/j.ccr.2008.05.005.","journal-title":"Cancer Cell"},{"issue":"1-2","key":"2476_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0027-5107(01)00078-1","volume":"475","author":"GJ Hageman","year":"2001","unstructured":"Hageman GJ, Stierum RH: Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. Mutat Res. 2001, 475 (1-2): 45-56.","journal-title":"Mutat Res"},{"issue":"6712","key":"2476_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/25292","volume":"396","author":"C Lengauer","year":"1998","unstructured":"Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature. 1998, 396 (6712): 643-649. 10.1038\/25292.","journal-title":"Nature"},{"issue":"5","key":"2476_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1046\/j.1440-1746.2000.02193.x","volume":"15","author":"F Nomura","year":"2000","unstructured":"Nomura F, Yaguchi M, Togawa A, Miyazaki M, Isobe K, Miyake M, Noda M, Nakai T: Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2000, 15 (5): 529-535. 10.1046\/j.1440-1746.2000.02193.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"49","key":"2476_CR12","doi-asserted-by":"publisher","first-page":"50754","DOI":"10.1074\/jbc.M408388200","volume":"279","author":"JR Revollo","year":"2004","unstructured":"Revollo JR, Grimm AA, Imai S: The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004, 279 (49): 50754-50763. 10.1074\/jbc.M408388200.","journal-title":"J Biol Chem"},{"issue":"2","key":"2476_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/MOG.0b013e32801b3c8f","volume":"23","author":"JR Revollo","year":"2007","unstructured":"Revollo JR, Grimm AA, Imai S: The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt\/PBEF\/visfatin in mammals. Curr Opin Gastroenterol. 2007, 23 (2): 164-170. 10.1097\/MOG.0b013e32801b3c8f.","journal-title":"Curr Opin Gastroenterol"},{"issue":"7","key":"2476_CR14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nsmb1105","volume":"13","author":"JA Khan","year":"2006","unstructured":"Khan JA, Tao X, Tong L: Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol. 2006, 13 (7): 582-588. 10.1038\/nsmb1105.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"2476_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jmb.2006.06.082","volume":"362","author":"MK Kim","year":"2006","unstructured":"Kim MK, Lee JH, Kim H, Park SJ, Kim SH, Kang GB, Lee YS, Kim JB, Kim KK, Suh SW, et al: Crystal structure of visfatin\/pre-B cell colony-enhancing factor 1\/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. J Mol Biol. 2006, 362 (1): 66-77. 10.1016\/j.jmb.2006.06.082.","journal-title":"J Mol Biol"},{"issue":"7","key":"2476_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nsmb1114","volume":"13","author":"T Wang","year":"2006","unstructured":"Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C: Structure of Nampt\/PBEF\/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol. 2006, 13 (7): 661-662. 10.1038\/nsmb1114.","journal-title":"Nat Struct Mol Biol"},{"issue":"21","key":"2476_CR17","first-page":"7436","volume":"63","author":"M Hasmann","year":"2003","unstructured":"Hasmann M, Schemainda I: FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003, 63 (21): 7436-7442.","journal-title":"Cancer Res"},{"issue":"1","key":"2476_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0005-2787(71)90012-8","volume":"238","author":"JB Clark","year":"1971","unstructured":"Clark JB, Ferris GM, Pinder S: Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5'-methyl nicotinamide. Biochim Biophys Acta. 1971, 238 (1): 82-85.","journal-title":"Biochim Biophys Acta"},{"issue":"51","key":"2476_CR19","doi-asserted-by":"publisher","first-page":"50985","DOI":"10.1074\/jbc.M306552200","volume":"278","author":"MD Jackson","year":"2003","unstructured":"Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM: Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone\/protein deacetylases. J Biol Chem. 2003, 278 (51): 50985-50998. 10.1074\/jbc.M306552200.","journal-title":"J Biol Chem"},{"issue":"31","key":"2476_CR20","doi-asserted-by":"publisher","first-page":"9249","DOI":"10.1021\/bi034959l","volume":"42","author":"AA Sauve","year":"2003","unstructured":"Sauve AA, Schramm VL: Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry. 2003, 42 (31): 9249-9256. 10.1021\/bi034959l.","journal-title":"Biochemistry"},{"issue":"14","key":"2476_CR21","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","volume":"113","author":"A Nahimana","year":"2009","unstructured":"Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjornelund J, Dawson KM, Dupuis M, Duchosal MA: The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood. 2009, 113 (14): 3276-3286. 10.1182\/blood-2008-08-173369.","journal-title":"Blood"},{"issue":"1","key":"2476_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10637-007-9083-2","volume":"26","author":"K Holen","year":"2008","unstructured":"Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR: The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs. 2008, 26 (1): 45-51. 10.1007\/s10637-007-9083-2.","journal-title":"Invest New Drugs"},{"issue":"22","key":"2476_CR23","first-page":"5751","volume":"59","author":"PJ Hjarnaa","year":"1999","unstructured":"Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, Skov T, Binderup L: CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. 1999, 59 (22): 5751-5757.","journal-title":"Cancer Res"},{"issue":"4","key":"2476_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.bbrc.2008.01.019","volume":"367","author":"UH Olesen","year":"2008","unstructured":"Olesen UH, Christensen MK, Bjorkling F, Jaattela M, Jensen PB, Sehested M, Nielsen SJ: Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008, 367 (4): 799-804. 10.1016\/j.bbrc.2008.01.019.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"2476_CR25","first-page":"2843","volume":"8","author":"P Hovstadius","year":"2002","unstructured":"Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, Bergh J, Karlsson MO, Lonnebo A, Ahlgren J: A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res. 2002, 8 (9): 2843-2850.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2476_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ejca.2004.12.023","volume":"41","author":"A Ravaud","year":"2005","unstructured":"Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, Droz JP, Fumoleau P, Twelves C: Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG\/EORTC study. Eur J Cancer. 2005, 41 (5): 702-707. 10.1016\/j.ejca.2004.12.023.","journal-title":"Eur J Cancer"},{"key":"2476_CR27","volume-title":"2009 ASCO Annual Meeting: 2009: ASCO","author":"M Pishvaian","year":"2009","unstructured":"Pishvaian M, Marshall J, Hwang J, Malik S, He A, Deeken J, Kelso C, Cotaria I, Berger M: A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. 2009 ASCO Annual Meeting: 2009: ASCO. 2009"},{"issue":"24","key":"2476_CR28","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1016\/S0960-894X(97)10152-4","volume":"7","author":"C Schou","year":"1997","unstructured":"Schou C, Ottosen ER, Petersen HJ, Bj\u00f6rkling F, Latini S, Hjarnaa PV, Bramm E, Binderup L: Novel cyanoguanidines with potent oral antitumour activity. Bioorg Med Chem Lett. 1997, 7 (24): 3095-3100. 10.1016\/S0960-894X(97)10152-4.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"2476_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bjc.1993.58","volume":"67","author":"PB Jensen","year":"1993","unstructured":"Jensen PB, Christensen IJ, Sehested M, Hansen HH, Vindelov L: Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer. 1993, 67 (2): 311-320.","journal-title":"Br J Cancer"},{"issue":"6","key":"2476_CR30","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1158\/1535-7163.MCT-09-1130","volume":"9","author":"UH Olesen","year":"2010","unstructured":"Olesen UH, Thougaard AV, Jensen PB, Sehested M: A preclinical study on the rescue of normal tissue by nicotinic acid in high dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther. 2010, 9 (6): 1609-1617. 10.1158\/1535-7163.MCT-09-1130.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2476_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0003-2697(80)90512-6","volume":"107","author":"GC Elliott","year":"1980","unstructured":"Elliott GC, Ajioka J, Okada CY: A rapid procedure for assaying nicotinamide phosphoribosyltransferase. Anal Biochem. 1980, 107 (1): 199-205. 10.1016\/0003-2697(80)90512-6.","journal-title":"Anal Biochem"},{"issue":"1","key":"2476_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.bbrc.2009.11.066","volume":"391","author":"A Garten","year":"2009","unstructured":"Garten A, Petzold S, Barnikol-Oettler A, Korner A, Thasler WE, Kratzsch J, Kiess W, Gebhardt R: Nicotinamide phosphoribosyltransferase (NAMPT\/PBEF\/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun. 2009, 391 (1): 376-381. 10.1016\/j.bbrc.2009.11.066.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2476_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0968-0004(02)02067-4","volume":"27","author":"C Mattos","year":"2002","unstructured":"Mattos C: Protein-water interactions in a dynamic world. Trends Biochem Sci. 2002, 27 (4): 203-208. 10.1016\/S0968-0004(02)02067-4.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"2476_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00001813-200401000-00008","volume":"15","author":"J Gullbo","year":"2004","unstructured":"Gullbo J, Lovborg H, Dhar S, Lukinius A, Oberg F, Nilsson K, Bjorkling F, Binderup L, Nygren P, Larsson R: Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828. Anticancer Drugs. 2004, 15 (1): 45-54. 10.1097\/00001813-200401000-00008.","journal-title":"Anticancer Drugs"},{"issue":"21","key":"2476_CR35","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1128\/MCB.00112-09","volume":"29","author":"M Watson","year":"2009","unstructured":"Watson M, Roulston A, Belec L, Billot X, Marcellus R, Bedard D, Bernier C, Branchaud S, Chan H, Dairi K, et al: The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors. Mol Cell Biol. 2009, 29 (21): 5872-5888. 10.1128\/MCB.00112-09.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"2476_CR36","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0022-3565(24)29239-9","volume":"299","author":"SB Hassan","year":"2001","unstructured":"Hassan SB, Jonsson E, Larsson R, Karlsson MO: Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. J Pharmacol Exp Ther. 2001, 299 (3): 1140-1147.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2476_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0014-2999(01)00925-6","volume":"417","author":"P Martinsson","year":"2001","unstructured":"Martinsson P, de la Torre M, Binderup L, Nygren P, Larsson R: Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. Eur J Pharmacol. 2001, 417 (3): 181-187. 10.1016\/S0014-2999(01)00925-6.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2476_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ijc.20255","volume":"111","author":"LS Olsen","year":"2004","unstructured":"Olsen LS, Hjarnaa PJ, Latini S, Holm PK, Larsson R, Bramm E, Binderup L, Madsen MW: Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int J Cancer. 2004, 111 (2): 198-205. 10.1002\/ijc.20255.","journal-title":"Int J Cancer"},{"issue":"5","key":"2476_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cmet.2007.09.003","volume":"6","author":"JR Revollo","year":"2007","unstructured":"Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, et al: Nampt\/PBEF\/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007, 6 (5): 363-375. 10.1016\/j.cmet.2007.09.003.","journal-title":"Cell Metab"},{"issue":"1","key":"2476_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00001813-200401000-00010","volume":"15","author":"P Hovstadius","year":"2004","unstructured":"Hovstadius P, Lindhagen E, Hassan S, Nilsson K, Jernberg-Wiklund H, Nygren P, Binderup L, Larsson R: Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines. Anticancer Drugs. 2004, 15 (1): 63-70. 10.1097\/00001813-200401000-00010.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"2476_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00423-004-0510-y","volume":"389","author":"A Formentini","year":"2004","unstructured":"Formentini A, Henne-Bruns D, Kornmann M: Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbecks Arch Surg. 2004, 389 (5): 405-413. 10.1007\/s00423-004-0510-y.","journal-title":"Langenbecks Arch Surg"},{"issue":"Suppl 4","key":"2476_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1179\/joc.2004.16.Supplement-1.25","volume":"16","author":"GJ Peters","year":"2004","unstructured":"Peters GJ, Smorenburg CH, Van Groeningen CJ: Prospective clinical trials using a pharmacogenetic\/pharmacogenomic approach. J Chemother. 2004, 16 (Suppl 4): 25-30.","journal-title":"J Chemother"},{"issue":"5","key":"2476_CR43","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1517\/14728222.11.5.695","volume":"11","author":"JA Khan","year":"2007","unstructured":"Khan JA, Forouhar F, Tao X, Tong L: Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets. 2007, 11 (5): 695-705. 10.1517\/14728222.11.5.695.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"2476_CR44","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/cmdc.200700311","volume":"3","author":"U Galli","year":"2008","unstructured":"Galli U, Ercolano E, Carraro L, Blasi Roman CR, Sorba G, Canonico PL, Genazzani AA, Tron GC, Billington RA: Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. ChemMedChem. 2008, 3 (5): 771-779. 10.1002\/cmdc.200700311.","journal-title":"ChemMedChem"},{"issue":"6","key":"2476_CR45","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10059-009-0088-x","volume":"27","author":"GB Kang","year":"2009","unstructured":"Kang GB, Bae MH, Kim MK, Im I, Kim YC, Eom SH: Crystal structure of Rattus norvegicus Visfatin\/PBEF\/Nampt in complex with an FK866-based inhibitor. Mol Cells. 2009, 27 (6): 667-671. 10.1007\/s10059-009-0088-x.","journal-title":"Mol Cells"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-677.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-677\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T17:50:23Z","timestamp":1740851423000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-677","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]},"article-number":"677"}}